Brief: Nyxoah Announces Acccess U.S. Pivotal Study Meets Primary Safety And Efficacy Endpoints In Complete Concentric Collapse Patients
BRIEF-Nyxoah Announces Acccess U.S. Pivotal Study Meets Primary Safety And Efficacy Endpoints In Complete Concentric Collapse Patients Sept 2 (Reuters) - Nyxoah SA NYXH.BR:
NYXOAH ANNOUNCES ACCCESS U.S. PIVOTAL STUDY MEETS PRIMARY SAFETY AND EFFICACY ENDPOINTS IN COMPLETE CONCENTRIC COLLAPSE PATIENTS
NYXOAH - REPORTS 12-MONTH ODI RESPONDER RATE OF 87.7% (P<0.001) ON FULL ANALYSIS SET
NYXOAH - REPORTS 12-MONTH AHI RESPONDER RATE OF 77.2% (P<0.001) ON FULL ANALYSIS SET
Source text: ID:nGNX5Qmj4X
Further company coverage: NYXH.BR
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nyxoah SA
See all newsBelgium's Nyxoah Q3 revenue rises on US commercialization
Brief: Nyxoah SA Q3 Gross Profit EUR 5.785 Million
Brief: Nyxoah SA Submits Pma Supplement To FDA To Expand Genio Indication To Complete Concentric Collapse Patients
Brief: Nyxoah Says Co Appoints Liam Kelly As Chief Executive Officer Effective October 1
Brief: Cvrx Appoints John Landry As Chief Financial Officer